巴曲酶注射液联合纤溶酶注射液治疗突发性耳聋患者的临床研究  

Clinical trial of batroxobin injection combined with plasmin injection in the treatment of sudden deafness

作　　者：赵艳 黄雅楠 曾成 何晶晶[2] ZHAO Yan;HUANG Ya-nan;ZENG Cheng;HE Jing-jing(Health Examination Department,Army 73 rd Group Miliary Hospital,Chenggong Hospital Afiliated to Xiamen University,Xiamen 361000,Fujian Province;Department of Otolaryngology-Heaad nd Neck Surgery,Xiamen Key Laboratory of Otolaryngology Head and Neck Surgery,The First Affiliated Hospital of Xiamen University,Teaching Hospital of Fujian Medical University,Xiamen 361000,Fujian Provincve,China)

机构地区：[1]中国人民解放军陆军第七十三集团军医院、厦门大学附属成功医院健康体检科,福建厦门361000 [2]厦门大学附属第一医院、福建医科大学教学医院耳鼻咽喉头颈外科、厦门市耳鼻咽喉头颈外科重点实验室,福建厦门361000

出　　处：《中国临床药理学杂志》2023年第6期786-790,共5页The Chinese Journal of Clinical Pharmacology

摘　　要：目的探讨巴曲酶注射液联合纤溶酶治疗突发性耳聋的临床疗效及安全性。方法将突发性耳聋患者作为研究对象,根据纤溶酶的用药情况,分为对照组和试验组。对照组在常规治疗基础上静脉滴注巴曲酶注射液10 BU,隔天1次,试验组在对照组基础上静脉滴注纤溶酶注射液100 U,隔天1次,均治疗2周。比较两组治疗后临床疗效、治疗前后纯音听阈、血液流变学及凝血功能指标,并统计治疗期间药物不良反应发生情况。结果本试验最终试验组和对照组分别纳入52例。本试验试验组和对照组分别纳入52例患者进行统计分析。治疗后,对照组和试验组纯音听阈分别为(49.91±4.95)和(37.78±5.47)dB;对照组全血高切黏度、全血低切黏度、血浆黏度分别为(4.98±0.72)、(10.27±1.11)、(1.67±0.30)mPa·s;试验组全血高切黏度、全血低切黏度、血浆黏度分别为(4.03±0.69)、(9.04±1.03)、(1.36±0.28)mPa·s;对照组活化部分凝血活酶时间(APTT)、凝血酶原时间(PT)及纤维蛋白原(FIB)分别为(30.09±4.03)s、(13.87±2.20)s、(2.55±0.79)g·L^(-1);试验组APTT、PT及FIB分别为(35.55±3.85)s、(15.93±2.35)s、(2.01±0.56)g·L^(-1);上述指标,试验组与对照组比较,差异均有统计学意义(均P<0.05)。结论巴曲酶与纤溶酶联合可更有效地改善突发性耳聋患者血液流变学和机体凝血功能,明显降低患耳纯音听阈,安全有效。Objective To explore the clinical efficacy and safety of batroxobin injection combined with plasmin in the treatment of sudden deafness.Method Patients with sudden deafness were divided into control group and treatment group according to the use of plasmin.The control group was treated with intravenous infusion of batroxobin injection10 BU on the basis of routine treatment,once every other day,and the treatment group was treated with intravenous infusion of plasmin injection100 U on the basis of the control group,once every other day.Both groups were treated for 2 weeks.The clinical efficacy after treatment,pure tone hearing threshold,blood rheology and coagulation function indexes before and after treatment were compared between the two groups.The incidence of dizziness and headache,upper abdominal pain,bleeding at the injection site,transient aminotransferase rise and other adverse drug reactions during the treatment were counted.Results The treatment group and the control group included 52 patients for statistical analysis.After treatment,the pure tone hearing thresholds of the control group and the treatment group were(49.91±4.95)and(37.78±5.47)d B,respectively;whole blood high shear viscosity,whole blood low shear viscosity and plasma viscosity in control group were(4.98±0.72),(10.27±1.11),(1.67±0.30)m Pa·s respectively;the whole blood high shear viscosity,whole blood low shear viscosity and plasma viscosity of the treatment group were(4.03±0.69),(9.04±1.03),(1.36±0.28)m Pa·s,respectively.The activated partial thromboplastin time(APTT),prothrombin time(PT)and fibrinogen(FIB)in the control group were(30.09±4.03)s,(13.87±2.20)s,(2.55±0.79)g·L^(-1),respectively.The APTT,PT and FIB in the treamtment group were(35.55±3.85)s,(15.93±2.35)s and(2.01±0.56)g·L^(-1),respectively.Compared treatment group with the control group,the differences of the above indicators were statistically significant(all P>0.05).Conclusion The combination of batroxobin and plasmin can more effectively improve the hemorheol

关 键 词：巴曲酶 纤溶酶 突发性耳聋 疗效 安全性 

分 类 号：R972[医药卫生—药品]